Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Editorial

Current Pharmaceutical Trends in Neuroimmunology – Part II: Autoimmunity Beyond the CNS and Other Disorders

Author(s): Paulus S. Rommer and Uwe K. Zettl

Volume 28, Issue 11, 2022

Published on: 31 May, 2022

Page: [853 - 853] Pages: 1

DOI: 10.2174/138161282811220531104017

Next »
[1]
Rommer PS, Zettl UK. Current Pharmaceutical Trends in Neuroimmunology - Part I: Disorders Affecting the CNS. Curr Pharm Des 2022; 28(6): 427.
[2]
Svačina MKR, Lehmann HC. Chronic inflammatory demyelinating polyneuropathy (CIDP): current therapies and future approaches. Curr Pharm Des 2022; 28(11): 854-62.
[3]
Glaubitz S, Zeng R, Rakocevic G, Schmidt J. Update on Myositis Therapy: from Today’s Standards to Tomorrow’s Possibilities. Curr Pharm Des 2022; 28(11): 863-80.
[4]
Mrak D, Bonelli M, Radner H. Neuropsychiatric systemic lupus erythematosus: a remaining challenge. Curr Pharm Des 2022; 28(11): 881-91.
[5]
Brakemeier S, Stolte B, Kleinschnitz C, Hagenacker T. Treatment of adult spinal muscular atrophy: overview and recent developments. Curr Pharm Des 2022; 28(11): 892-8.

© 2024 Bentham Science Publishers | Privacy Policy